Persephoni Launches Strategic Sponsorship with American Cancer Society’s BrightEdge to Accelerate Oncology Innovation

Persephoni Launches Strategic Sponsorship with American Cancer Society’s BrightEdge to Accelerate Oncology Innovation

Notified -...

GEn1E Lifesciences appoints François Nader, MD as Chair of its Board of Directors

GEn1E Lifesciences appoints François Nader, MD as Chair of its Board of Directors

Notified -...

Io Therapeutics, Inc., presented data from studies of IRX4204, the company’s phase II clinical stage RXR agonist for treatment of normal aging-related neurodegeneration, at the FASEB Science Research Conference on Cellular and Molecular Mechanisms of Brai

Io Therapeutics, Inc., presented data from studies of IRX4204, the company’s phase II clinical stage RXR agonist for treatment of normal aging-related neurodegeneration, at the FASEB Science Research Conference on Cellular and Molecular Mechanisms of Brai

...

Io Therapeutics, Inc., presented data from studies of IRX4204, the company’s phase II clinical stage RXR agonist for treatment of normal aging-related neurodegeneration, at the FASEB Science Research Conference on Cellular and Molecular Mechanisms of Brai

Io Therapeutics, Inc., presented data from studies of IRX4204, the company’s phase II clinical stage RXR agonist for treatment of normal aging-related neurodegeneration, at the FASEB Science Research Conference on Cellular and Molecular Mechanisms of Brai

Notified -...

menu
menu